A new study provides fresh insights into how THC interacts with the human body to provide therapeutic effects.
In various European countries and North America, cannabis-based medicines are authorised for therapeutic purposes.
While the cannabis plant contains over 100 cannabinoids, THC (D9-tetrahydrocannabinol) and CBD (cannabidiol) are the two best known and characterised constituents.
THC and CBD are administered under different pharmaceutical forms, showing therapeutic effects such as pain and inflammation relief. Based on clinical trials, cannabinoid-containing medications have been shown to help alleviate symptoms of disorders such as epilepsy, Alzheimer’s disease, asthma, and cancer.
However, little is known about how THC and other cannabinoids work in the human body at the molecular level.
Now a team of researchers from the European Molecular Biology Laboratory (EMBL) Grenoble have investigated the interaction between THC and some proteins it might bind to.
In a recent study, they showed in vitro that THC inhibits an important human enzyme called autotaxin.
This enzyme is involved in many different cellular functions, specifically producing a molecule called lysophosphatidic acid (LPA), which stimulates cell proliferation. A dysregulation of LPA production can lead to development of cancer, inflammation, or pulmonary fibrosis.
As a result, autotaxin is a major target for drug development.
New molecular insights on THC
Understanding how THC and other cannabinoids interact in our cells at the atomic level would help to administer THC more efficiently in therapeutic contexts.
The field of structural biology is particularly relevant to obtain this kind of information. Structural biologists focus on explaining at the atomic scale, the three-dimensional structure of molecules, like proteins or enzymes, and how they interact with each other.
These structural results further lead to understanding molecules’ particular function and how to modulate their activities with specific compounds – which are crucial insights to develop effective drugs.
The first step in structural and biochemical studies is to determine how a specific component interacts with molecules in vitro – meaning in the controlled environment of the laboratory – before going for further investigation in vivo, in living organisms.
During their investigation of THC, the team obtained the three-dimensional structure of the THC cannabinoid bound with autotaxin. By employing macromolecular crystallography with EMBL’s beamline at the PETRA III synchrotron in Hamburg, they could lay the molecular basis of how THC inhibits this enzyme.
A path to further investigations
Identifying this enzyme as a binding target for THC expands the knowledge on this cannabinoid and provides more data on its possible therapeutic effects at the molecular level and how cannabis might contribute to therapy.
Mathias Eymery, PhD student on the McCarthy team and first author of the publication, commented: “Autotaxin is an essential enzyme in human beings.
“It is responsible for the production of LPA, a major membrane-derived lipid signalling molecule that mediates many different cellular functions. Dysregulations of LPA production by autotaxin are known to have a role in the development of cancer, inflammation, or pulmonary fibrosis.”
The paper highlights recent studies highlighting the potential of medicinal cannabis as a treatment for tissue fibrosis and glaucoma, the leading cause of blindness worldwide, both of which have been shown to have links to autotaxin and LPA.
Several inhibitors targeting autotaxin are under clinical investigation for their therapeutic use against idiopathic pulmonary fibrosis. According to the authors, an ongoing trial on one of these drugs was discontinued over a ‘risk-benefit concern’.
They state: “In this context, our observation that THC is a partial inhibitor of ATX is of great interest, because this molecule is an FDA-approved drug, which could reduce LPA levels incompletely.
“Moreover, the fact that THC can cross the blood–brain barrier makes it an attractive candidate to manipulate neuronal diseases, where the brain-specific isoform of ATX is involved.”
The researchers say that In vivo studies are necessary to confirm that the binding between autotaxin and THC is linked to the therapeutic effects of THC administration, as the main known targets of THC in the human body are the CB1 and CB2 cannabinoid receptors, that mediate the psychoactive and pain relieving effects of cannabinoids.
Further investigation will help determine further potential of cannabinoids for medical research and drug development.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure
- Science6 months ago
New research suggests alcohol, not cannabis, is the real ‘gateway’ drug